Trial Profile
Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; 3BNC 117; Antiretrovirals
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms eCLEAR
- 10 Oct 2019 Planned primary completion date changed from 20 Jan 2020 to 20 Mar 2020.
- 12 Apr 2019 Planned End Date changed from 14 Nov 2018 to 20 Apr 2021.
- 12 Apr 2019 Planned primary completion date changed from 20 Jan 2019 to 20 Jan 2020.